<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: The Company ", fill: "#a9ba9d"},
{source: "3: The Company ", target: "3: qualified opinion", fill: "#a9ba9d"},
{source: "3: The Company ", target: "4: The Company ", fill: "#ff355e"},
{source: "4: The Company ", target: "4: encounter competitive technological financial", fill: "#ff355e"},
{source: "4: encounter competitive technological financial", target: "4: challenges", fill: "#ff355e"},
{source: "4: challenges", target: "4: difficult than", fill: "#ff355e"},
{source: "4: difficult than", target: "4: market may", fill: "#ff355e"},
{source: "4: market may", target: "4: existing key management", fill: "#ff355e"},
{source: "4: existing key management", target: "4: pending litigation", fill: "#ff355e"},
{source: "4: pending litigation", target: "4: raise additional capital", fill: "#ff355e"},
{source: "4: raise additional capital", target: "4: operations", fill: "#ff355e"},
{source: "4: The Company ", target: "5: Assumptions ", fill: "#fdf5e6"},
{source: "5: Assumptions ", target: "5: budgeting marketing", fill: "#fdf5e6"},
{source: "5: budgeting marketing", target: "5: management decisions", fill: "#fdf5e6"},
{source: "5: management decisions", target: "5: thus susceptible", fill: "#fdf5e6"},
{source: "5: thus susceptible", target: "5: interpretations", fill: "#fdf5e6"},
{source: "5: interpretations", target: "5: periodic revisions based on actual", fill: "#fdf5e6"},
{source: "5: periodic revisions based on actual", target: "5: developments", fill: "#fdf5e6"},
{source: "5: developments", target: "5: budgets which may", fill: "#fdf5e6"},
{source: "5: budgets which may", target: "5: financial position", fill: "#fdf5e6"},
{source: "5: financial position", target: "5: operations", fill: "#fdf5e6"},
{source: "5: Assumptions ", target: "13: further increase", fill: "#fff600"},
{source: "13: further increase", target: "13: expenditures", fill: "#fff600"},
{source: "13: expenditures", target: "13: development", fill: "#fff600"},
{source: "13: development", target: "13: commercialization", fill: "#fff600"},
{source: "13: commercialization", target: "13: new products", fill: "#fff600"},
{source: "13: new products", target: "13: ensure compliance with", fill: "#fff600"},
{source: "13: ensure compliance with", target: "13: marketing capabilities", fill: "#fff600"},
{source: "13: further increase", target: "17: characterized", fill: "#f7e98e"},
{source: "17: characterized", target: "17: by rapidly evolving", fill: "#f7e98e"},
{source: "17: by rapidly evolving", target: "17: technology", fill: "#f7e98e"},
{source: "17: technology", target: "17: intense competition", fill: "#f7e98e"},
{source: "17: characterized", target: "20: explosives detection equipment market", fill: "#aa4069"},
{source: "20: explosives detection equipment market", target: "20: substantially greater", fill: "#aa4069"},
{source: "20: substantially greater", target: "20: capital resources greater research", fill: "#aa4069"},
{source: "20: capital resources greater research", target: "20: development manufacturing", fill: "#aa4069"},
{source: "20: development manufacturing", target: "20: marketing resources", fill: "#aa4069"},
{source: "20: marketing resources", target: "20: greater name recognition than", fill: "#aa4069"},
{source: "20: explosives detection equipment market", target: "29: radioactive prostate seeds brachytherapy", fill: "#fdd5b1"},
{source: "29: radioactive prostate seeds brachytherapy", target: "29: sources orthopedic implant coatings", fill: "#fdd5b1"},
{source: "29: sources orthopedic implant coatings", target: "29: radiopaque coatings will", fill: "#fdd5b1"},
{source: "29: radiopaque coatings will", target: "29: acceptance", fill: "#fdd5b1"},
{source: "29: acceptance", target: "29: acceptance by", fill: "#fdd5b1"},
{source: "29: acceptance by", target: "29: medical community", fill: "#fdd5b1"},
{source: "29: medical community", target: "29: generally", fill: "#fdd5b1"},
{source: "29: radioactive prostate seeds brachytherapy", target: "30: market acceptance", fill: "#fc0"},
{source: "30: market acceptance", target: "30: services will also depend upon", fill: "#fc0"},
{source: "30: services will also depend upon", target: "30: regulatory approvals", fill: "#fc0"},
{source: "30: regulatory approvals", target: "30: establishment", fill: "#fc0"},
{source: "30: establishment", target: "30: demonstration", fill: "#fc0"},
{source: "30: demonstration", target: "30: medical community", fill: "#fc0"},
{source: "30: medical community", target: "30: among health care payers", fill: "#fc0"},
{source: "30: among health care payers", target: "30: clinical safety efficacy", fill: "#fc0"},
{source: "30: clinical safety efficacy", target: "30: cost effectiveness", fill: "#fc0"},
{source: "30: market acceptance", target: "37: explosives detection products", fill: "#555"},
{source: "37: explosives detection products", target: "37: technologies may", fill: "#555"},
{source: "37: technologies may", target: "37: accepted by", fill: "#555"},
{source: "37: accepted by", target: "37: government", fill: "#555"},
{source: "37: government", target: "37: agencies airports", fill: "#555"},
{source: "37: agencies airports", target: "37: airlines which could harm", fill: "#555"},
{source: "37: airlines which could harm", target: "37: financial performance", fill: "#555"},
{source: "37: explosives detection products", target: "START_HERE", fill: "#555"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Semiconductors and Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Semiconductors</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance">Acceptance</a></td>
      <td>Acceptance in human psychology is a person's assent to the reality of a situation, recognizing a process or condition (often a negative or uncomfortable situation) without attempting to change it or protest it. The concept is close in meaning to acquiescence, derived from the Latin acquiēscere (to find rest in).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_testing">Acceptance testing</a></td>
      <td>In engineering and its various subdisciplines, acceptance testing is a test conducted to determine if the requirements of a specification or contract are met. It may involve chemical tests, physical tests, or performance tests.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_(novel)">Acceptance (novel)</a></td>
      <td>Acceptance is a 2014 novel by Jeff VanderMeer. It is the last in a series of three books called the Southern Reach Trilogy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Offer_and_acceptance">Offer and acceptance</a></td>
      <td>Offer and acceptance are generally recognised as essential requirements for the formation of a contract, and analysis of their operation is a traditional approach in contract law. The offer and acceptance formula, developed in the 19th century, identifies a moment of formation when the parties are of one mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-acceptance">Self-acceptance</a></td>
      <td>Self-acceptance is acceptance of self.\n\n\n== Definition ==\nSelf-acceptance can be defined as:\n\nthe awareness of one's strengths and weaknesses,\nthe realistic (yet subjective) appraisal of one's talents, capabilities, and general worth, and,\nfeelings of satisfaction with one's self despite deficiencies and regardless of past behaviors and choices.According to Shepard, self-acceptance is an individual's satisfaction or happiness with oneself, and is thought to be necessary for good mental health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fat_acceptance_movement">Fat acceptance movement</a></td>
      <td>The fat acceptance movement, also known as fat pride, fat empowerment, and fat activism, is a social movement seeking to eliminate the social stigma of fatness from social attitudes by pointing out to the general public the social obstacles faced by fat people. Areas of contention include the aesthetic, legal, and medical approaches to people whose bodies are fatter than the social norm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Credit_Acceptance">Credit Acceptance</a></td>
      <td>Credit Acceptance Corporation is an auto finance company providing automobile loans and other related financial products. The company operates its financial program through a national network of dealer-partners, the automobile dealers participating in the programs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intrusion_detection_system">Intrusion detection system</a></td>
      <td>An intrusion detection system (IDS; also intrusion prevention system or IPS) is a device or software application that monitors a network or systems for malicious activity or policy violations. Any intrusion activity or violation is typically reported either to an administrator or collected centrally using a security information and event management (SIEM) system.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IMPLANT SCIENCES CORP      ITEM 1A RISK FACTORS     This Report on Form 10-K contains certain forward-looking statements that     are <font color="blue">based on current expectations</font></td>
    </tr>
    <tr>
      <td>In light of the <font color="blue">important factors</font> that     can <font color="blue">materially affect</font> results, including those set forth in this paragraph     and below, the inclusion of forward-looking information <font color="blue">herein should</font> not be     regarded as a <font color="blue">representation by</font> the Company or any other person that the     <font color="blue">objectives</font>  or  plans of the Company will be achieved</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has     received a <font color="blue">qualified opinion</font> that it is a going concern</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may     encounter <font color="blue">competitive</font>, <font color="blue">technological</font>, financial and business <font color="blue">challenges</font>     making it more <font color="blue"><font color="blue">difficult</font> than</font> expected to continue to develop and market its     products;  the <font color="blue">market may</font> not accept the Companyapstas existing and future     products;  the Company may be unable to retain <font color="blue">existing key <font color="blue">management</font></font>     personnel; the Company has <font color="blue">pending litigation</font>; the Company has net losses;     the Company may not be able to <font color="blue">raise <font color="blue">additional</font> capital</font>; and there may be     other material adverse changes in the Companyapstas <font color="blue">operations</font> or business</td>
    </tr>
    <tr>
      <td><font color="blue">Assumptions </font>relating to budgeting, marketing, and other <font color="blue"><font color="blue">management</font> decisions</font>     are subjective in many respects and <font color="blue">thus susceptible</font> to <font color="blue">interpretations</font> and     <font color="blue">periodic revisions based on actual</font> experience and business <font color="blue"><font color="blue">development</font>s</font>, the     impact of which may cause the Company to alter its marketing, or other     budgets, which may in turn affect the Companyapstas <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The reader is therefore cautioned not to place undue     reliance on forward-looking statements contained herein, which speak solely     as of the date of this Form 10-K <font color="blue">The Company </font>assumes <font color="blue">no responsibility</font> to     update any forward-looking statements as a result of new information, future     events, or otherwise</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors should</font> be considered <font color="blue">carefully</font> in evaluating the     Company and its business:       <font color="blue">The Company </font>has received a <font color="blue">modified audit opinion on</font> its ability to continue     as a going concern</td>
    </tr>
    <tr>
      <td>The audit report our <font color="blue"><font color="blue">independent</font> registered public <font color="blue">accounting</font> firm</font> issued on     our <font color="blue">audited financial statements</font> for the <font color="blue">fiscal year</font> ended June 30, 2006     contains  a  <font color="blue">modification</font> regarding our ability to <font color="blue">continue as</font> a going     concern</td>
    </tr>
    <tr>
      <td>This <font color="blue">modification</font> indicates that there is substantial doubt on the     part  of our <font color="blue"><font color="blue">independent</font> registered public <font color="blue">accounting</font> firm</font> that we can     <font color="blue">continue as</font> a going concern in that we did not have <font color="blue">sufficient cash</font> and     <font color="blue">liquid assets at</font> June 30, 2006, to cover our operating <font color="blue">capital <font color="blue">requirements</font></font>     for the next twelve-month period and if <font color="blue">sufficient cash</font> cannot be obtained     we would have to <font color="blue"><font color="blue">substantially</font> alter</font> our <font color="blue">operations</font>, or we may be forced to     discontinue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Such an opinion from our <font color="blue">independent</font> registered     public <font color="blue">accounting</font> firm may limit our ability to access certain types of     financing, or may prevent us from obtaining financing on acceptable terms</td>
    </tr>
    <tr>
      <td>During  the  twelve  months  ended  June  30,  2006, we had a net loss     of approximately dlra7cmam084cmam000 and a <font color="blue">net loss applicable</font> to <font color="blue">common shareholders</font>     of approximately dlra8cmam173cmam000</td>
    </tr>
    <tr>
      <td>We plan to <font color="blue">further increase</font> our <font color="blue">expenditures</font>     to complete the <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">new products</font>, to     <font color="blue">ensure compliance with</font> the Food and Drug Administrationapstas Quality System     Regulations  and to broaden our sales and <font color="blue">marketing <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">accumulated</font>  deficit  as  of  June 30, 2006 is     approximately dlra36cmam290cmam000</td>
    </tr>
    <tr>
      <td>Intense <font color="blue">competition</font> and <font color="blue">rapid <font color="blue">technological</font></font> change <font color="blue">could harm</font> our financial     performance</td>
    </tr>
    <tr>
      <td>The  medical  device  industry  is  <font color="blue">characterized</font>  <font color="blue">by rapidly evolving</font>     <font color="blue">technology</font> and intense <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>In our <font color="blue">radioactive</font> products, such as     <font color="blue">prostate seed implants</font> and <font color="blue"><font color="blue">radioactive</font> brachytherapy devices</font>, we compete     with many other <font color="blue">companies selling</font> similar <font color="blue">products with certain</font> of such     <font color="blue">companies serving <font color="blue">substantially</font></font> the <font color="blue">entire <font color="blue">radioactive</font> prostate seed market</font></td>
    </tr>
    <tr>
      <td>In  our <font color="blue">semiconductor market</font> we <font color="blue">compete with</font> many companies, including     companies that have in-house <font color="blue">capabilities</font> to implant, diagnose and repair     their own wafers</td>
    </tr>
    <tr>
      <td>In our <font color="blue">explosives <font color="blue">detection</font> equipment market</font>, we compete     with many companies, including companies that have <font color="blue"><font color="blue">substantially</font> greater</font>     capital resources, greater research and <font color="blue">development</font>, <font color="blue">manufacturing</font> and     <font color="blue">marketing resources</font> and experience and <font color="blue">greater name recognition than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, we expect <font color="blue">new entrants into</font> our markets</td>
    </tr>
    <tr>
      <td>There can be no     assurance that our <font color="blue"><font color="blue">competitors</font> will</font> not succeed in developing or marketing     <font color="blue">technologies</font> and products that are more <font color="blue"><font color="blue">effective</font> than</font> our products or that     would render our <font color="blue">products obsolete</font> or <font color="blue">non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>Moreover, there can be     no assurance that we will be able to price our products and <font color="blue">services at</font> or     below  the  prices  of <font color="blue">competing products</font> and <font color="blue">technologies</font> in order to     <font color="blue">facilitate market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>In addition, new procedures and <font color="blue">medications</font>     could be developed that replace or reduce the importance of procedures that     use our products</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">success will depend</font>, in part, on our     ability to respond quickly to medical and <font color="blue">technological</font> changes through the     <font color="blue">development</font> and <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">development</font> involves a high degree of risk, and there can be no assurance     that our new product <font color="blue">development</font> efforts will result in any <font color="blue">commercially</font>     <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>Our failure to compete or respond to <font color="blue">technological</font>     change in an <font color="blue"><font color="blue">effective</font> manner would</font> have a material <font color="blue">adverse affect on</font> our     business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">medical products</font> and <font color="blue">technologies</font> may not be <font color="blue">accepted by</font> the medical     <font color="blue">community</font> which <font color="blue">could harm</font> our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue"><font color="blue">radioactive</font> prostate seeds</font>, brachytherapy     sources, orthopedic implant coatings, or <font color="blue">radiopaque coatings will</font> achieve     <font color="blue">acceptance</font>, or continue to receive <font color="blue">acceptance</font>, by the <font color="blue">medical <font color="blue">community</font></font> and     market  <font color="blue">acceptance</font>  <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>The degree of market <font color="blue">acceptance</font> for our     products and <font color="blue"><font color="blue">services will also</font> depend upon</font> a number of factors, including     the receipt and timing of <font color="blue"><font color="blue">regulatory</font> approvals</font> and the <font color="blue">establishment</font> and     <font color="blue">demonstration</font> in the <font color="blue">medical <font color="blue">community</font></font> and <font color="blue">among health care payers</font> of the     clinical safety, efficacy and <font color="blue">cost <font color="blue">effective</font>ness</font> of our products</td>
    </tr>
    <tr>
      <td>Certain of     the  medical <font color="blue">indications</font> that can be treated by our devices or devices     treated using our coatings can also be treated by other medical procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Decisions </font>to purchase our products will primarily be influenced by members     of the <font color="blue">medical <font color="blue">community</font></font>, who will have the choice of <font color="blue">recommending medical</font>     <font color="blue">treatments</font>,  such  as  <font color="blue">radiotherapeutic seeds</font>, or the more traditional     <font color="blue">alternative</font>s, such as surgery and <font color="blue">external beam radiation therapy</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font><font color="blue">alternative</font>  <font color="blue">treatments</font>  currently  are <font color="blue">widely accepted</font> in the medical     <font color="blue">community</font> and have a <font color="blue">long history</font> of use</td>
    </tr>
    <tr>
      <td>There can be no assurance that our     devices or <font color="blue">technologies</font> will be able to replace such established <font color="blue">treatments</font>     or that physicians, health care payers, patients or the <font color="blue">medical <font color="blue">community</font></font> in     <font color="blue">general will accept</font> and utilize our devices or any other <font color="blue">medical products</font>     that may be developed or <font color="blue">treated by us even</font> if <font color="blue">regulatory</font> and <font color="blue">reimbursement</font>     approvals are obtained</td>
    </tr>
    <tr>
      <td>Long-term market <font color="blue">acceptance</font> of our products and     services will depend, in part, on the <font color="blue">capabilities</font>, operating features and     price  of  our products and <font color="blue">technologies</font> as compared to those of other     <font color="blue">available products</font> and services</td>
    </tr>
    <tr>
      <td>Failure of our products and <font color="blue">technologies</font> to     <font color="blue">gain market</font> <font color="blue">acceptance</font> would have a material adverse effect on our business     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>_________________________________________________________________         Our <font color="blue">explosives <font color="blue">detection</font> products</font> and <font color="blue">technologies</font> may not be <font color="blue">accepted by</font>     <font color="blue">government</font>  agencies, airports or airlines which <font color="blue">could harm</font> our future     <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">explosives <font color="blue">detection</font> systems will</font> achieve     <font color="blue">acceptance</font> by the domestic and <font color="blue">international</font> airports, <font color="blue">government</font> agencies     and  airlines,  and  market <font color="blue">acceptance</font> <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>The degree of market     <font color="blue">acceptance</font> for our <font color="blue">explosives <font color="blue">detection</font> products</font> and <font color="blue">services will also</font>     depend  upon  a number of factors, including the receipt and timing of     <font color="blue"><font color="blue">regulatory</font> approvals</font> and the <font color="blue">establishment</font> and <font color="blue">demonstration</font> of the ability     of our proposed device to detect <font color="blue">trace explosives residues on personnel</font>,     baggage and other <font color="blue">cargo prior</font> to <font color="blue">embarking on aircraft</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">profitability</font> depends on whether</font> our products can <font color="blue">successfully</font>     compete in the <font color="blue">commercial marketplace</font></td>
    </tr>
    <tr>
      <td>We  currently  market  <font color="blue"><font color="blue">radioactive</font> prostate seeds</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also provide ion</font>     <font color="blue">implantation services</font> for <font color="blue">ion implantation</font> of <font color="blue">semiconductors</font> and medical     devices</td>
    </tr>
    <tr>
      <td>We     plan to <font color="blue">market radiopaque coatings</font>, and <font color="blue">explosive <font color="blue">detection</font> systems</font> that may     require substantial <font color="blue">further investment</font> in research, product <font color="blue">development</font>,     preclinical and <font color="blue">clinical testing</font> and <font color="blue">government</font>al <font color="blue"><font color="blue">regulatory</font> approvals</font> prior     to being marketed and sold</td>
    </tr>
    <tr>
      <td>Our ability to increase revenues and achieve     <font color="blue">profitability</font> and positive <font color="blue">cash flow will depend</font>, in part, on our ability to     complete such product <font color="blue">development</font> efforts, obtain such <font color="blue"><font color="blue">regulatory</font> approvals</font>,     and  establish  <font color="blue">manufacturing</font>  and  <font color="blue">marketing programs</font> and <font color="blue">gain market</font>     <font color="blue">acceptance</font> for <font color="blue">such proposed products</font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue">explosive <font color="blue">detection</font> systems</font> is <font color="blue">intensely <font color="blue">competitive</font></font> and is     <font color="blue">characterized</font>  by  <font color="blue">continuously</font>  developing  <font color="blue">technology</font>  and  frequent     <font color="blue">introduction</font>s  of  <font color="blue">new products</font> and features</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">competition</font> to     increase  as other <font color="blue">companies introduce <font color="blue">additional</font></font> and more <font color="blue">competitive</font>     products  in  the <font color="blue">explosive <font color="blue">detection</font> systems</font> market as we develop the     <font color="blue">capabilities</font> and <font color="blue">enhancements</font> of our <font color="blue">trace <font color="blue">detection</font> systems</font></td>
    </tr>
    <tr>
      <td>Each of our     <font color="blue">competitors</font> may have <font color="blue"><font color="blue">substantially</font> greater</font> financial resources than us</td>
    </tr>
    <tr>
      <td>We believe that our ability to compete in the <font color="blue">explosive <font color="blue">detection</font> systems</font>     market is <font color="blue">based upon</font> such factors as: product performance, functionality,     quality and features; quality of customer support services, documentation     and training; and the <font color="blue">capability</font> of the <font color="blue">technology</font> to appeal to broader     <font color="blue">applications beyond</font> the inspection of passengers, baggage, and cargo carried     on airlines</td>
    </tr>
    <tr>
      <td>Although we believe that our currently developed product has     all of the <font color="blue">capabilities</font> to meet the <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font>’s decree that     all passengers, baggage, and cargo carried <font color="blue">on airlines must</font> be screened     thoroughly,  certain of our <font color="blue">competitors</font> may have an <font color="blue">advantage over</font> our     existing <font color="blue">technology</font> <font color="blue">with respect</font> to these factors</td>
    </tr>
    <tr>
      <td>There can be no assurance     that  we will be successful in <font color="blue">convincing potential customers</font> that our     products  will be superior to other systems given all of the <font color="blue">necessary</font>     performance  criteria,  that  new  systems  <font color="blue">with comparable</font> or greater     performance, lower price and faster or <font color="blue">equivalent throughput will</font> not be     introduced, or that, if <font color="blue">such products</font> are introduced, customers will not     delay or <font color="blue">cancel potential orders</font> for us yet to be <font color="blue">commercialized system</font></td>
    </tr>
    <tr>
      <td>Further,  there  can  be no assurance that we will be able to bring to     <font color="blue">commercialization</font> and <font color="blue">further enhance</font> our product to <font color="blue">better compete on</font> the     basis of cost, throughput, accommodation of <font color="blue">detection</font> of passengers, baggage     or other cargo carried <font color="blue">onto airlines</font>, or that we <font color="blue">will otherwise</font> be able to     compete <font color="blue">successfully</font> with existing or new <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> efforts are subject to the <font color="blue">risks inherent</font> in the     <font color="blue">development</font> of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>These risks include the <font color="blue">possibility</font> that     <font color="blue">development</font> costs will be much <font color="blue">greater than currently</font> anticipated, that our     products will be found to be <font color="blue">in<font color="blue">effective</font></font> or unsafe, or <font color="blue">will otherwise</font> fail     to  receive  <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approvals</font>; that the products will be     <font color="blue">difficult</font> to <font color="blue"><font color="blue">manufacture</font> on</font> a large scale or be uneconomical to market; that     the <font color="blue">proprietary rights</font> of <font color="blue"><font color="blue">third parties</font> will interfere with</font> our product     <font color="blue">development</font>;  or that <font color="blue"><font color="blue">third parties</font> will market</font> superior or equivalent     <font color="blue">products which</font> achieve greater market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Furthermore, there can be     no assurance that we will be able to conduct our product <font color="blue">development</font> efforts     within the time <font color="blue">frames currently</font> anticipated or that <font color="blue">such efforts will</font> be     completed <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>There are risks relating to our Development, Distribution and Manufacturing     <font color="blue">Agreement </font>with Rapiscan Systems, Inc</td>
    </tr>
    <tr>
      <td>In  March  of  2005,  we  <font color="blue">entered into</font> a Development, Distribution and     Manufacturing  <font color="blue">Agreement </font>(the “Agreement”) with Rapiscan Systems, Inc</td>
    </tr>
    <tr>
      <td>Under the terms of this <font color="blue">agreement</font>, we gave Rapiscan the     exclusive worldwide rights to market our Quantum Sniffer^TM portable and     benchtop trace <font color="blue">detection</font> devices under their <font color="blue">private label</font></td>
    </tr>
    <tr>
      <td>We also agreed     to give Rapiscan the exclusive worldwide rights to distribute certain other     new security <font color="blue">products which</font> we may develop in the <font color="blue">future with</font> their funding,     <font color="blue">as well as rights</font>, in some <font color="blue">circumstances</font>, to <font color="blue"><font color="blue">manufacture</font> certain components</font>     of the Quantum Sniffer^TM portable and benchtop trace <font color="blue">detection</font> devices</td>
    </tr>
    <tr>
      <td>In March 2006, the Company <font color="blue">brought suit against</font> Rapiscan and its parent, OSI     Systems, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">requesting rescission</font> of the Agreement, for     lack of performance and other grounds or in the <font color="blue">alternative</font>, termination of     the <font color="blue">Agreement </font>due to material breaches of contract and implied covenant of     good  faith  and  fair  dealing and for damages</td>
    </tr>
    <tr>
      <td><font color="blue">Should the Company </font>be     <font color="blue">unsuccessful</font> in prosecuting its lawsuit, it could have a material adverse     effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Rapiscan’s complaint is based     upon  claims  of  breach  of contract, breach of warranty and tortuous     <font color="blue">interference with contractual relations</font> and is requesting a decree for     specific performance, declaratory relief and <font color="blue">injunctive relief</font></td>
    </tr>
    <tr>
      <td>Should the     Company be <font color="blue">unsuccessful</font> in <font color="blue">defending itself</font> in the lawsuit, it could have a     material adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font>on our ability to protect our <font color="blue">intellectual property</font> or continue     to use our <font color="blue">intellectual property</font> <font color="blue">could harm</font> our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">compete <font color="blue">effective</font>ly will depend</font>, to a <font color="blue">significant</font> extent, on     our ability to operate <font color="blue">without infringing</font> the <font color="blue">intellectual property</font> rights     of others</td>
    </tr>
    <tr>
      <td>Many <font color="blue">participants</font> in the medical device <font color="blue">area aggressively seek</font>     patent  protection  and  have  <font color="blue">increasing numbers</font> of patents, and have     <font color="blue">frequently demonstrated</font> a <font color="blue">readiness</font> to <font color="blue">commence litigation based on patent</font>     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Third  parties  may  assert  <font color="blue">exclusive patent rights</font> to     <font color="blue">technologies</font> that are important to us</td>
    </tr>
    <tr>
      <td>Although we have seventeen <font color="blue"><font color="blue">United States</font> </font><font color="blue">patents issued</font> and nine United     States <font color="blue">patent applications pending</font> for our <font color="blue">technology</font> and processes, our     <font color="blue">success will depend</font>, in part, on our ability to obtain the <font color="blue">patents applied</font>     for and maintain <font color="blue">trade secret protection</font> for our <font color="blue">technology</font> and operate     <font color="blue">without infringing</font> on the <font color="blue">proprietary rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>The validity     and breadth of claims in medical <font color="blue">technology</font> patents involve complex legal     and factual questions and, therefore, may be <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>No assurance     can be given that any <font color="blue">pending patent applications</font> or any <font color="blue">future patent</font>     <font color="blue">application will issue as patents</font>, that the scope of any <font color="blue">patent protection</font>     obtained will be sufficient to exclude <font color="blue">competitors</font> or provide <font color="blue">competitive</font>     <font color="blue">advantages</font> to us, that any of our <font color="blue">patents will</font> be held valid if <font color="blue">subsequently</font>     challenged or that others will not claim rights in or ownership of the     patents and other <font color="blue">proprietary rights</font> held by us</td>
    </tr>
    <tr>
      <td>_________________________________________________________________         Our medical device products and services are subject to extensive <font color="blue">government</font>     regulation</td>
    </tr>
    <tr>
      <td>If we fail to obtain or are delayed in obtaining the approval of     the <font color="blue">necessary</font> federal and state <font color="blue">government</font> agencies, our business could be     <font color="blue">materially affect</font>ed</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of our medical device products and services are     subject  to  extensive  regulation  <font color="blue">principally</font>  by  the Food and Drug     Administration in the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue">corresponding</font> foreign <font color="blue">regulatory</font>     agencies in each country in which we sell our products</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font>     affect product approvals, product standards, packaging <font color="blue">requirements</font>, design     <font color="blue">requirements</font>,  <font color="blue">manufacturing</font>  and  quality assurance, labeling, import     restrictions, tariffs and other tax <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Securing Food and Drug     Administration <font color="blue">authorizations</font> and approvals requires submission of extensive     clinical  data  and  supporting  information</td>
    </tr>
    <tr>
      <td>In  <font color="blue">most instances</font>, the     <font color="blue">manufacture</font>rs or licensees of <font color="blue">medical devices</font> that are <font color="blue">treated by us will</font> be     responsible  for  securing  <font color="blue">regulatory</font>  approval  for  <font color="blue">medical devices</font>     <font color="blue">incorporating</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>There  can  be  no  assurance that our medical device     <font color="blue">manufacture</font>rs or <font color="blue">licensees will</font> be able to obtain <font color="blue">regulatory</font> clearance or     approval for devices <font color="blue">incorporating</font> our <font color="blue">technology</font> on a <font color="blue">timely basis</font>, or at     all</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>clearance or approvals, if granted, may include <font color="blue">significant</font>     <font color="blue">limitations</font> of the <font color="blue">indicated uses</font> for which the <font color="blue">product may</font> be marketed</td>
    </tr>
    <tr>
      <td>In     addition, product clearance or <font color="blue">approval could</font> be withdrawn for failure to     <font color="blue">comply with</font> <font color="blue">regulatory</font> standards or the occurrence of <font color="blue">unforeseen problems</font>     <font color="blue">following initial marketing</font></td>
    </tr>
    <tr>
      <td>Changes in existing <font color="blue">regulations</font> or adoption of     new <font color="blue">government</font>al <font color="blue">regulations</font> or policies could prevent or delay <font color="blue">regulatory</font>     approval  of  products  <font color="blue">incorporating</font>  our <font color="blue">technology</font> or subject us to     <font color="blue">additional</font> regulation</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">Food and <font color="blue">Drug Administration </font></font>regulation, certain of our     <font color="blue">activities</font> are <font color="blue">regulated by</font>, and require <font color="blue">approvals from</font>, other federal and     state agencies</td>
    </tr>
    <tr>
      <td>The use, <font color="blue">management</font>, transportation, and disposal of certain     materials and wastes are subject to <font color="blue">regulation by several federal</font> and state     <font color="blue">agencies depending on</font> the nature of the materials or waste material</td>
    </tr>
    <tr>
      <td><font color="blue">Certain     </font>toxic chemicals and <font color="blue">products containing toxic chemicals may</font> require special     reporting to the <font color="blue"><font color="blue">United States</font> </font>Environmental Protection Agency and/or its     state <font color="blue">counterparts</font></td>
    </tr>
    <tr>
      <td>Our future <font color="blue">operations</font> may require <font color="blue">additional</font> approvals     from federal and/or state <font color="blue">environmental agencies</font></td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will be able to obtain <font color="blue">necessary</font> <font color="blue">government</font> approvals, or that we     will be able to operate with the <font color="blue">conditions</font> that may be attached to future     <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>While it is our policy to     <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, failure to <font color="blue"><font color="blue">comply with</font> existing</font> or     future <font color="blue">regulatory</font> <font color="blue">requirements</font> and failure to obtain or maintain <font color="blue">necessary</font>     <font color="blue">approvals could</font> have a material adverse effect on our business, financial     condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure or delay of our medical device <font color="blue">manufacture</font>rs in obtaining Food and     <font color="blue">Drug Administration </font>and other <font color="blue">necessary</font> <font color="blue">regulatory</font> clearance or approval,     the loss of <font color="blue">previously</font> obtained clearance or approvals, as well as failure     to <font color="blue">comply with</font> other existing or future <font color="blue">regulatory</font> <font color="blue">requirements</font> could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>certain  of  our  products  utilize  <font color="blue">radiation sources</font>, their     <font color="blue">manufacture</font>, distribution, transportation, import/export, use and disposal     will also be subject to federal, state and/or local laws and <font color="blue">regulations</font>     relating  to the use, handling, procurement and storage of <font color="blue">radioactive</font>     materials</td>
    </tr>
    <tr>
      <td>We  must  also  comply  with  United  States Department of     <font color="blue">Transportation </font><font color="blue">regulations</font> on the labeling and packaging <font color="blue">requirements</font> for     shipment of <font color="blue">radiation sources</font> to hospitals or other users of our products</td>
    </tr>
    <tr>
      <td>We expect that there will be comparable <font color="blue">regulatory</font> <font color="blue">requirements</font> and/or     approvals in <font color="blue">markets outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If any of the foregoing     approvals are <font color="blue">significant</font>ly delayed or not obtained, our business could be     <font color="blue">materially <font color="blue">adversely affected</font></font></td>
    </tr>
    <tr>
      <td>We  depend  on  third  party <font color="blue">reimbursement</font> to our customers for market     <font color="blue">acceptance</font> of our <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">third party</font> payors fail</font> to provide     <font color="blue">appropriate levels</font> of <font color="blue">reimbursement</font> for our products, our <font color="blue">profitability</font>     would be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>Medicare, Medicaid and other <font color="blue">government</font> insurance programs, as well as     private insurance <font color="blue">reimbursement</font> programs greatly affect suppliers of health     care  products</td>
    </tr>
    <tr>
      <td><font color="blue">Several  </font>of the products being developed, produced or     <font color="blue">processed by us</font>, including our orthopedic implants, prostate seeds, and     <font color="blue">interventional cardiology instruments</font> and devices, are currently being     reimbursed  by  third  <font color="blue">party payers</font></td>
    </tr>
    <tr>
      <td>Our customers rely on third-party     <font color="blue">reimbursement</font>s to cover all or part of the costs of most of the procedures     in  which  our products are used</td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payers</font> (including health     maintenance organizations) may affect the pricing or <font color="blue">relative attractiveness</font>     of our <font color="blue">products by regulating</font> the <font color="blue">maximum amount</font> of <font color="blue">reimbursement</font> provided     <font color="blue">by such payers</font> to the physicians, hospitals and <font color="blue">clinics using</font> our devices,     or by taking the position that such <font color="blue">reimbursement</font> is not <font color="blue">available at</font> all</td>
    </tr>
    <tr>
      <td>The amounts of <font color="blue">reimbursement</font> by third <font color="blue">party payers</font> in those states that do     provide <font color="blue">reimbursement</font> vary considerably</td>
    </tr>
    <tr>
      <td>Alternatively, a diagnostic-related group may be assigned that does not     reflect the costs associated with the use of our devices or devices treated     using our services, resulting in limited <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If, for any reason,     the cost of using our products or services was not to be <font color="blue">reimbursed by third</font>     party  payers,  our ability to sell our products and <font color="blue">services would</font> be     <font color="blue">materially <font color="blue">adversely affected</font></font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">international</font> market, <font color="blue">reimbursement</font> by     private <font color="blue">third party</font> medical insurance providers and <font color="blue">government</font>al insurers     and providers varies from country to country</td>
    </tr>
    <tr>
      <td>In <font color="blue">certain countries</font>, our     ability  to achieve <font color="blue">significant</font> market penetration may depend upon the     <font color="blue">availability</font> of <font color="blue">third party</font> <font color="blue">government</font>al <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims could damage our reputation and hurt our financial     results</td>
    </tr>
    <tr>
      <td>To date no product <font color="blue">liability</font> claims have been asserted <font color="blue">against us</font>; however,     the testing, marketing and sale of <font color="blue">implantable devices</font> and <font color="blue">materials entail</font>     an <font color="blue">inherent risk</font> that product <font color="blue">liability</font> claims will be asserted <font color="blue">against us</font>,     if the use of our devices is alleged to have <font color="blue">adverse effects on</font> a patient,     including <font color="blue">exacerbation</font> of a patientapstas condition, further injury, or death</td>
    </tr>
    <tr>
      <td>A     product <font color="blue">liability</font> claim or a <font color="blue">product recall could</font> have a material adverse     effect on our business</td>
    </tr>
    <tr>
      <td>Certain of our devices are designed to be used in     <font color="blue">treatments</font>  of  diseases where there is a high risk of serious medical     <font color="blue">complications</font> or death</td>
    </tr>
    <tr>
      <td>Although we have obtained product <font color="blue">liability</font> insurance coverage on medical     products, there can be no assurance that in the future we will be able to     obtain <font color="blue">such coverage on</font> acceptable terms or that <font color="blue">insurance will provide</font>     <font color="blue">adequate coverage against</font> any or all potential claims</td>
    </tr>
    <tr>
      <td><font color="blue">Furthermore </font>there can     be no assurance that we will avoid <font color="blue">significant</font> product <font color="blue">liability</font> claims and     the <font color="blue">attendant adverse publicity</font></td>
    </tr>
    <tr>
      <td>Any product <font color="blue">liability</font> claim or other claim     <font color="blue">with respect</font> to <font color="blue">underinsured liabilities could</font> have a material adverse     effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>_________________________________________________________________         If our contract <font color="blue">manufacture</font>r cannot provide the services we require, our     ability to <font color="blue">manufacture</font> our <font color="blue">products could</font> be harmed</td>
    </tr>
    <tr>
      <td>We rely on a single contract <font color="blue">manufacture</font>r to provide <font color="blue">manufacturing</font> services     for our <font color="blue">explosives <font color="blue">detection</font> products</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">services become unavailable</font>,     we would be required to identify and <font color="blue">enter into</font> an <font color="blue">agreement</font> with a new     contract <font color="blue">manufacture</font>r or take the <font color="blue">manufacturing</font> in house</td>
    </tr>
    <tr>
      <td>The loss of our     contract <font color="blue">manufacture</font>r could <font color="blue">significant</font>ly disrupt production as well as     increase the cost of production, thereby also increasing the prices of our     products</td>
    </tr>
    <tr>
      <td>These changes could have a material adverse effect on our business     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we  were to lose the services of either our president or our chief     scientist, our business would be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">substantially</font> dependent, for the foreseeable future, upon our     Chairman of the Board, President and Chief Executive Officer, Dr</td>
    </tr>
    <tr>
      <td>Anthony J     Armini and our Vice President and Chief Scientist, Dr</td>
    </tr>
    <tr>
      <td>Stephen N Bunker,     both of <font color="blue">whom currently devote</font> their full time and efforts to <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">entered into</font> an employment <font color="blue">agreement</font> with each of these officers</td>
    </tr>
    <tr>
      <td><font color="blue">Armini or Dr</font></td>
    </tr>
    <tr>
      <td>Bunker for any <font color="blue">significant</font>     period of time, our business would be <font color="blue">materially <font color="blue">adversely affected</font></font></td>
    </tr>
    <tr>
      <td>We will be required to redeem the <font color="blue">Series D Preferred </font>for cash if the five     day average market price of our <font color="blue">common stock</font>, prior to a <font color="blue">redemption date</font>, is     less than 110prca of the fixed <font color="blue"><font color="blue">conversion</font> price</font></td>
    </tr>
    <tr>
      <td>We  will  be required to redeem the <font color="blue">Series D Preferred </font>for cash if the     following <font color="blue">conditions</font> are not met: (1) the shares must be issued pursuant to     an <font color="blue">effective</font> <font color="blue">registration</font> statement, (2) the average closing market price of     the <font color="blue">common stock</font> for the <font color="blue">five trading days immediately preceding</font> a payment     <font color="blue">date must exceed</font> the fixed <font color="blue"><font color="blue">conversion</font> price</font> of dlra4dtta15 by 110prca and no one     day’s closing price may be less than the fixed <font color="blue"><font color="blue">conversion</font> price</font>, and (3) the     <font color="blue"><font color="blue">conversion</font> dollar value may</font> not exceed the aggregate of the prior 22 trading     days’ dollar volume</td>
    </tr>
    <tr>
      <td>We cannot be certain that we will be able to redeem the     <font color="blue">monthly payment</font> in shares of <font color="blue"><font color="blue">common stock</font> on</font> a <font color="blue">redemption date</font> given the     fixed <font color="blue"><font color="blue">conversion</font> price</font> of the <font color="blue">preferred stock</font> and the <font color="blue">associated market</font>     price of the <font color="blue"><font color="blue">common stock</font> on</font> a <font color="blue">redemption date</font></td>
    </tr>
    <tr>
      <td>If we are required to redeem     <font color="blue">monthly payment</font>s in cash, this will reduce our working capital <font color="blue">necessary</font> for     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We     may be required to reduce or curtail certain <font color="blue">operations</font> and research and     <font color="blue">development</font> projects to improve our <font color="blue">cash resources</font></td>
    </tr>
    <tr>
      <td>If  third  party  credit  is unavailable, our working <font color="blue">capital could</font> be     restricted; restrictions on our ability to <font color="blue">raise <font color="blue">additional</font> capital</font> under     certain <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>Currently, we <font color="blue">rely on cash generated from</font> our <font color="blue">operations</font>, private equity     financing and <font color="blue">third party</font> credit for working <font color="blue">capital purposes</font></td>
    </tr>
    <tr>
      <td>If such     financing is no longer <font color="blue">available at</font> acceptable rates, we would be required     to reduce or curtail our <font color="blue">operations</font> and research and <font color="blue">development</font> projects</td>
    </tr>
    <tr>
      <td>This would have a material adverse effect on our business and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, from March 4, 2005 and for a period 24 months thereafter, we are     <font color="blue">prohibited from issuing</font> or selling any debt or equity securities that are     convertible into, exchangeable or exercisable for, or include the right to     receive <font color="blue">additional</font> shares of our <font color="blue">common stock</font> either:       ·     At a <font color="blue">conversion</font>, exercise or exchange rate or other price that is <font color="blue">based upon</font>     and/or varies with the <font color="blue">trading prices</font> of or quotations for the shares of our     <font color="blue">common stock</font> at any time after the initial issuance of such debt or equity     securities, or       ·     With a <font color="blue">conversion</font>, exercise or exchange price that is subject to being reset     at some future date after the initial issuance of such debt or equity     security or upon the occurrence of specified or <font color="blue">contingent</font> events directly     or <font color="blue">indirectly</font> related to our business or the market for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>To the extent that these <font color="blue">prohibitions</font> affect our ability to raise <font color="blue">additional</font>     capital from potential future investors, we would be required to reduce or     curtail our <font color="blue">operations</font> and research and <font color="blue">development</font> projects</td>
    </tr>
    <tr>
      <td>This would     have a material adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>